Limits...
CT Perfusion Imaging Can Predict Patients' Survival and Early Response to Transarterial Chemo-Lipiodol Infusion for Liver Metastases from Colorectal Cancers.

Lv WF, Han JK, Cheng DL, Zhou CZ, Ni M, Lu D - Korean J Radiol (2015)

Bottom Line: The percentage change of CTPI parameters of target lesions were compared between responders and non-responders at 1 month after TACLI.The best cut-off value was -21.5% and patients who exhibited a ≥ 21.5% decrease in HAP had a significantly higher overall survival rate than those who exhibited a < 21.5% decrease (p < 0.001).The percentage change in HAP after TACLI with a cutoff value of -21.5% is the optimal predictor.

View Article: PubMed Central - PubMed

Affiliation: PET/CT Center, Qilu Hospital, First Affiliated Hospital of Shandong University, Jinan 250012, China. ; Department of Radiology, Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei 230001, China.

ABSTRACT

Objective: To prospectively evaluate the performance of computed tomography perfusion imaging (CTPI) in predicting the early response to transarterial chemo-lipiodol infusion (TACLI) and survival of patients with colorectal cancer liver metastases (CRLM).

Materials and methods: Computed tomography perfusion imaging was performed before and 1 month after TACLI in 61 consecutive patients. Therapeutic response was evaluated on CT scans 1 month and 4 months after TACLI; the patients were classified as responders and non-responders based on 4-month CT scans after TACLI. The percentage change of CTPI parameters of target lesions were compared between responders and non-responders at 1 month after TACLI. The optimal parameter and cutoff value were determined. The patients were divided into 2 subgroups according to the cutoff value. The log-rank test was used to compare the survival rates of the 2 subgroups.

Results: Four-month images were obtained from 58 patients, of which 39.7% were responders and 60.3% were non-responders. The percentage change in hepatic arterial perfusion (HAP) 1 month after TACLI was the optimal predicting parameter (p = 0.003). The best cut-off value was -21.5% and patients who exhibited a ≥ 21.5% decrease in HAP had a significantly higher overall survival rate than those who exhibited a < 21.5% decrease (p < 0.001).

Conclusion: Computed tomography perfusion imaging can predict the early response to TACLI and survival of patients with CRLM. The percentage change in HAP after TACLI with a cutoff value of -21.5% is the optimal predictor.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier estimates of overall survival period from start of transarterial chemo-lipiodol infusion (TACLI).Kaplan-Meier curves for percentage changes in hepatic arterial perfusion (HAP) 1 month after TACLI reveal that Subgroup A (decrease of ≥ 21.5% in percentage changes in HAP) has significantly higher overall survival than Subgroup B (with decrease of < 21.5%) (log-rank test, p < 0.001).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4499545&req=5

Figure 4: Kaplan-Meier estimates of overall survival period from start of transarterial chemo-lipiodol infusion (TACLI).Kaplan-Meier curves for percentage changes in hepatic arterial perfusion (HAP) 1 month after TACLI reveal that Subgroup A (decrease of ≥ 21.5% in percentage changes in HAP) has significantly higher overall survival than Subgroup B (with decrease of < 21.5%) (log-rank test, p < 0.001).

Mentions: The 6-month, 12-month, and 18-month survival rates in Subgroup A were 96.3% (95% CI, 89.2% to 100%), 74.5% (95% CI, 56.6% to 92.3%), and 24.5% (95% CI, 0 to 51.4%), respectively. The survival rates in Subgroup B were 70.6% (95% CI, 55.3% to 85.9%), 28% (95% CI, 12.8% to 43.4%), and 18.8% (95% CI, 4.7% to 36.9%), respectively. Subgroup A had a significantly higher overall survival [median survival time, 455.2 days (95% CI, 411.3 to 499.1 days)] than Subgroup B (median survival time, 295.2 days [95% CI, 237.7 to 352.7 days]) (χ2 = 13.169, p < 0.001) (Fig. 4).


CT Perfusion Imaging Can Predict Patients' Survival and Early Response to Transarterial Chemo-Lipiodol Infusion for Liver Metastases from Colorectal Cancers.

Lv WF, Han JK, Cheng DL, Zhou CZ, Ni M, Lu D - Korean J Radiol (2015)

Kaplan-Meier estimates of overall survival period from start of transarterial chemo-lipiodol infusion (TACLI).Kaplan-Meier curves for percentage changes in hepatic arterial perfusion (HAP) 1 month after TACLI reveal that Subgroup A (decrease of ≥ 21.5% in percentage changes in HAP) has significantly higher overall survival than Subgroup B (with decrease of < 21.5%) (log-rank test, p < 0.001).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4499545&req=5

Figure 4: Kaplan-Meier estimates of overall survival period from start of transarterial chemo-lipiodol infusion (TACLI).Kaplan-Meier curves for percentage changes in hepatic arterial perfusion (HAP) 1 month after TACLI reveal that Subgroup A (decrease of ≥ 21.5% in percentage changes in HAP) has significantly higher overall survival than Subgroup B (with decrease of < 21.5%) (log-rank test, p < 0.001).
Mentions: The 6-month, 12-month, and 18-month survival rates in Subgroup A were 96.3% (95% CI, 89.2% to 100%), 74.5% (95% CI, 56.6% to 92.3%), and 24.5% (95% CI, 0 to 51.4%), respectively. The survival rates in Subgroup B were 70.6% (95% CI, 55.3% to 85.9%), 28% (95% CI, 12.8% to 43.4%), and 18.8% (95% CI, 4.7% to 36.9%), respectively. Subgroup A had a significantly higher overall survival [median survival time, 455.2 days (95% CI, 411.3 to 499.1 days)] than Subgroup B (median survival time, 295.2 days [95% CI, 237.7 to 352.7 days]) (χ2 = 13.169, p < 0.001) (Fig. 4).

Bottom Line: The percentage change of CTPI parameters of target lesions were compared between responders and non-responders at 1 month after TACLI.The best cut-off value was -21.5% and patients who exhibited a ≥ 21.5% decrease in HAP had a significantly higher overall survival rate than those who exhibited a < 21.5% decrease (p < 0.001).The percentage change in HAP after TACLI with a cutoff value of -21.5% is the optimal predictor.

View Article: PubMed Central - PubMed

Affiliation: PET/CT Center, Qilu Hospital, First Affiliated Hospital of Shandong University, Jinan 250012, China. ; Department of Radiology, Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei 230001, China.

ABSTRACT

Objective: To prospectively evaluate the performance of computed tomography perfusion imaging (CTPI) in predicting the early response to transarterial chemo-lipiodol infusion (TACLI) and survival of patients with colorectal cancer liver metastases (CRLM).

Materials and methods: Computed tomography perfusion imaging was performed before and 1 month after TACLI in 61 consecutive patients. Therapeutic response was evaluated on CT scans 1 month and 4 months after TACLI; the patients were classified as responders and non-responders based on 4-month CT scans after TACLI. The percentage change of CTPI parameters of target lesions were compared between responders and non-responders at 1 month after TACLI. The optimal parameter and cutoff value were determined. The patients were divided into 2 subgroups according to the cutoff value. The log-rank test was used to compare the survival rates of the 2 subgroups.

Results: Four-month images were obtained from 58 patients, of which 39.7% were responders and 60.3% were non-responders. The percentage change in hepatic arterial perfusion (HAP) 1 month after TACLI was the optimal predicting parameter (p = 0.003). The best cut-off value was -21.5% and patients who exhibited a ≥ 21.5% decrease in HAP had a significantly higher overall survival rate than those who exhibited a < 21.5% decrease (p < 0.001).

Conclusion: Computed tomography perfusion imaging can predict the early response to TACLI and survival of patients with CRLM. The percentage change in HAP after TACLI with a cutoff value of -21.5% is the optimal predictor.

No MeSH data available.


Related in: MedlinePlus